US Capabilities Wilmington PharmaTech is a U.S.-based CRDMO with end-to-end small molecule API development, HPAPIs, peptides, ADC payloads, and dedicated FTE research, offering onshore cGMP manufacturing and analytical services which can appeal to domestically-focused pharma and biotech clients seeking reliable U.S. supply chains.

Expansion Momentum A $50 million campus expansion in Delaware doubling API reactor capacity signals increased production throughput and capacity to support growing client programs, presenting opportunities to engage mid-to-late stage companies needing scale-up and commercial API manufacturing.

Senior Leadership Recent leadership appointments, including a Chief Commercial Officer and a Managing Director/Board member, indicate a sharpened focus on growth, client partnerships, and strategic account development—ideal for enterprise sales outreach and targeted relationship-building.

Strategic Positioning Ownership of cGMP API manufacturing in the United States with capabilities across discovery to commercial scale, including process development, analytical testing, technology transfer, and impurity/polymorph studies, positions WPT as a one-stop CRDMO for complex small molecules seeking end-to-end outsourcing.

Financial and Market Signals Revenue is in the mid-range of 50–100 million with active investment in capacity and assets; this suggests growing demand and a readiness to partner on long-cycle programs, making WPT a compelling candidate for collaboration on high-potency APIs, HPAPIs, and specialty intermediates.